<DOC>
	<DOCNO>NCT00407446</DOCNO>
	<brief_summary>To test hypothesis long-term PDE5-inhibition overexpressing nitric oxide pathway beneficial chronic heart failure patient . Double-blind placebo-controlled trial . Primary end-points : quality life exercise performance</brief_summary>
	<brief_title>PDE5-Inhibition With Sildenafil Chronic Heart Failure</brief_title>
	<detailed_description>In chronic heart failure ( CHF ) , endothelial function ( EF ) deterioration muscle underperfusion elicit ergoreflex exercise oversignaling , hyperventilation breathlessness . PDE5 inhibition , improve EF , might beneficial . We test hypothesis long-term therapeutic trial . CHF patient randomly assign placebo ( 23 case , group 1 ) sildenafil ( 23 case , group 2 ) addition current antifailure therapy , 6 month . In group 2 group 1 , assessment 3 6 month show following change : reduction systolic pulmonary artery pressure ( -25.2 –29.0 % ) , ergoreflex effect ventilation ( -66.6 -72.5 % ) , ventilation CO2 production slope ( VE/VCO2 , -14.0 -16.0 % ) breathlessness ( -29.6 -27.1 % ) ; increase brachial artery flow-mediated dilatation ( FMD , +57.6 +67.0 % ) , peak exercise O2 uptake ( peak VO2 , +25.0 +26.3 % ) ratio VO2 work rate change ( VO2WR , +20.7 +22.0 % ) . These change significant p &lt; 0.01 . In group 2 group 1 , significant correlation find , 3 6 month , change FMD ergoreflex VE . Changes ergoreflex correlate peak VO2 VE/VCO2 slope . No remarkable side effect note , flush 3 patient . In CHF , benefit sildenafil sustain consist improvement EF , modulation ergoreflex signaling , attenuation exercise hyperventilation breathlessness , increase aerobic efficiency exercise performance . Thus , sildenafil affect peripheral mechanism breathlessness may view effective safe adjunct therapeutic armamentarium CHF .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Eligibility criterion : consent participate study detail information procedure , possible clinical benefit risk ; ability complete maximal exercise test ; force expiratory volume 1 sec/forced vital capacity ratio &gt; 70 % ; left ventricular ejection fraction  45 % , determine echocardiography . Patients recruit systolic blood pressure &gt; 140 &lt; 110 mmHg , diabetes mellitus , therapy nitrate preparation , history sildenafil intolerance , significant lung valvular disease , neuromuscular disorder , exerciseinduced myocardial ischemia , atrial fibrillation ( 6 ) , claudication , peripheral vascular disease .</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>PDE5 inhibition</keyword>
	<keyword>chronic heart failure</keyword>
	<keyword>endothelial function</keyword>
	<keyword>exercise ventilation</keyword>
</DOC>